H.I.G. Capital, a prominent global alternative investment firm, continues to make waves in the investment landscape. With $65 billion in capital under management, the firm has been actively pursuing opportunities in healthcare and adjacent industries, demonstrating its commitment to sectors with robust growth potential.
Recently, H.I.G. Capital announced its acquisition of SkinCure Oncology, a leader in non-invasive cancer treatment solutions. This move underlines H.I.G.’s keen interest in innovative healthcare technologies. SkinCure Oncology, known for its image-guided superficial radiation therapy, has already partnered with over 500 physicians, offering treatments to more than 100,000 patients. This acquisition marks a significant step for H.I.G. as it taps into the expanding market for advanced cancer therapies.
In another strategic transaction, H.I.G. Capital completed the sale of BIOVECTRA, a contract development and manufacturing organization, to Agilent Technologies for a whopping $925 million. This sale reflects H.I.G.’s adeptness at nurturing and scaling businesses, having significantly expanded BIOVECTRA’s capabilities since its acquisition in 2019.
Not stopping there, H.I.G. Capital ventured into the natural products sector by acquiring a majority stake in Naturalia Tantum S.p.A., an Italian firm specializing in organic beauty and personal care products. This acquisition showcases H.I.G.’s versatility and its interest in the burgeoning market for natural and organic consumer goods.
Additionally, H.I.G. Capital’s purchase of Action Elevator highlights its strategic approach to supporting healthcare infrastructure, further broadening its portfolio. By expanding its presence in the Mid-Atlantic region’s elevator services market, H.I.G. is setting the stage for future growth opportunities.
Overall, H.I.G. Capital’s latest moves illustrate a calculated strategy to enhance its investment portfolio across diverse and promising sectors.